CAPRICOR THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$266.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- CAPRICOR THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$182.43M, a 1141.99% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $17.51M.
- CAPRICOR THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$8.48M, a 946.09% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $1.00M, a 95.73% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $276.56M.
- CAPRICOR THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$3.41M, a 166.93% decline from fiscal 2023.
- CAPRICOR THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $5.09M.
- CAPRICOR THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$25.28M, a 1239.14% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$266.91M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$182.43M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $276.56M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $8.22M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $11.95M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | $17.51M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | -$3.41M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $53.68M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | -$4.01M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | -$8.48M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $5.09M 10-K · filed 2025-03-26 | |||
| 2023-09-30 | -$618.58K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $233.89K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$25.28M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | -$26.47M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$18.49M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $23.45M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $2.22M 10-K · filed 2023-03-17 | |||
| 2021-09-30 | $8.17M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $5.41M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $9.21M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $28.77M 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $31.40M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $32.35M 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | $9.32M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$645.77K 10-K · filed 2021-03-15 | |||
| 2019-09-30 | $2.52M 10-Q · filed 2020-11-13 | |||
| 2019-06-30 | $1.58M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $2.81M 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | -$2.34M 10-K · filed 2020-03-27 | |||
| 2018-09-30 | -$2.08M 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | -$11.44K 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $906.55K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $2.33M 10-K · filed 2019-03-29 | |||
| 2017-09-30 | $4.96M 10-Q · filed 2018-11-14 | |||
| 2017-06-30 | $4.54M 10-Q · filed 2018-08-13 | |||
| 2017-03-31 | -$675.30K 10-Q · filed 2018-05-14 | |||
| 2016-12-31 | -$1.02M 10-K · filed 2018-03-22 | |||
| 2016-09-30 | $13.05M 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | $3.28M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |